STAT5 in Cancer and Immunity

Journal of Interferon and Cytokine Research

Volumn 36, Issue 4, 2016, Pages 226-237

  Rani, Aradhana ^a   Murphy, John J ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; GROWTH FACTOR; INTERLEUKIN 2; JANUS KINASE; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; CYTOKINE;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUMOYLATION; TUMOR IMMUNITY; TUMOR INVASION; ANIMAL; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM;

ANIMALS; CARCINOGENESIS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; IMMUNITY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84964220748     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0054     Document Type: Article

References (164)

1. Aaronson DS, Horvath CM. 2002. A road map for those who don't know JAK-STAT. Science 296(5573):1653-1655.
2. Aoki N, Matsuda T. 2000. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 275(50):39718-39726.
3. Aoki N, Matsuda T. 2002. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRLmediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 16(1):58-69.
4. Azam M, et al. 1995. Interleukin-3 signals through multiple isoforms of Stat5. EMBO J 14(7):1402-1411.
5. Barash I. 2006. Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol 209(2):305-313.
6. Baxter EJ, et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464): 1054-1061.
7. Becker S, Groner B, Muller CW. 1998. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394(6689):145-151.
8. Berger A, et al. 2014. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia 28(3):629-641.
9. Bhattacharya S, et al. 1996. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 383(6598):344-347.
10. Bhattacharya S, Schindler C. 2003. Regulation of Stat3 nuclear export. J Clin Invest 111(4):553-559.
11. Boucheron C, et al. 1998. A single amino acid in the DNA binding regions of STAT5Aand STAT5B confers distinctDNAbinding specificities. J Biol Chem 273(51):33936-33941.
12. Bowman T, et al. 2000. STATs in oncogenesis. Oncogene 19(21):2474-2488.
13. Britschgi A, et al. 2012. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22(6):796-811.
14. Brivanlou AH, Darnell JE, Jr. 2002. Signal transduction and the control of gene expression. Science 295(5556):813-818.
15. Bromberg J. 2002. Stat proteins and oncogenesis. J Clin Invest 109(9):1139-1142.
16. Brown S, Zeidler MP. 2008. Unphosphorylated STATs go nuclear. Curr Opin Genet Dev 18(5):455-460.
17. Buettner R, Mora LB, Jove R. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945-954.
18. Burchill MA, et al. 2007. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178(1):280-290.
19. Caffarel MM, et al. 2012. Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death Differ 19(3):511-522.
20. Casetti L, et al. 2013. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res 73(7):2052-2058.
21. Chen X, et al. 1998. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93(5):827-839.
22. Chen X, et al. 2003a. A reinterpretation of the dimerization interface of the N-terminal domains of STATs. Protein Sci 12(2):361-365.
23. Chen Y, et al. 2003b. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 278(19):16520-16527.
24. Chen Y, et al. 2006. Proteasome-dependent down-regulation of activated Stat5A in the nucleus. Blood 108(2):566-574.
25. Chughtai N, et al. 2002. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem 277(34): 31107-31114.
26. Clark DE, et al. 2005. ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. J Biol Chem 280(25):24175-24180.
27. Copeland NG, et al. 1995. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29(1):225-228.
28. Cotarla I, et al. 2004. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108(5):665-671.
29. Cui Y, et al. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24(18):8037-8047.
30. Darnell JE, Jr. 1997. STATs and gene regulation. Science 277(5332):1630-1635.
31. Darnell JE, Jr., Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421.
32. Decker T, et al. 2002. IFNs and STATs in innate immunity to microorganisms. J Clin Invest 109(10):1271-1277.
33. Decker T, Kovarik P. 2000. Serine phosphorylation of STATs. Oncogene 19(21):2628-2637.
34. Dieudonne FX, et al. 2013. Promotion of osteoblast differentiation in mesenchymal cells through Cbl-mediated control of STAT5 activity. Stem Cells 31(7):1340-1349.
35. Ehret GB, et al. 2001. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276(9):6675-6688.
36. Engblom D, et al. 2007. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturationrelated gene expression. Genes Dev 21(10):1157-1162.
37. Friedbichler K, et al. 2010. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 116(9):1548-1558.
38. Friedrich K, et al. 1999. Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation. Int Immunol 11(8):1283-1294.
39. Fung MM, et al. 2005. IL-2-and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1. Oncogene 24(29):4624-4633.
40. Germeshausen M, Ballmaier M, Welte K. 2007. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 109(1):93-99.
41. Gewinner C, et al. 2004. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279(5):3563-3572.
42. Gingras S, et al. 1999. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Res 27(13):2722-2729.
43. Gouilleux-Gruart V, et al. 1997. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma 28(1-2):83-88.
44. Groner B, et al. 2000. Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Horm IGF Res 10 Suppl B:S15-S20.
45. Hayakawa F, Naoe T. 2006. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci 1086:213-222.
46. Hochhaus A, La Rosee P. 2004. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18(8):1321-1331.
47. Hoelbl A, et al. 2006. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107(12):4898-4906.
48. Horvath CM. 2000. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 25(10): 496-502.
49. Horvath CM, Wen Z, Darnell JE, Jr. 1995. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9(8):984-994.
50. Hoyt R, et al. 2007. Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol 179(6):3402-3406.
51. Humphreys RC, Hennighausen L. 1999. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10(10): 685-694.
52. Iavnilovitch E, et al. 2004. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 112(4):607-619.
53. Iavnilovitch E, Groner B, Barash I. 2002. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1(1):32-47.
54. Ihle JN. 1996. STATs and MAPKs: obligate or opportunistic partners in signaling. Bioessays 18(2):95-98.
55. Ilaria RL, Jr., Van Etten RA. 1996. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704-31710.
56. Imada K, et al. 1998. Stat5b is essential for natural killer cellmediated proliferation and cytolytic activity. J Exp Med 188(11):2067-2074.
57. Jackson PK. 2001. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15(23):3053-3058.
58. John S, et al. 1999. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 19(3): 1910-1918.
59. Joliot V, et al. 2006. Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. Oncogene 25(33):4573-4584.
60. Kagami S, et al. 2000. Both stat5a and stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood 95(4):1370-1377.
61. Kazansky AV, et al. 1999. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 274(32):22484-22492.
62. Kelly J, et al. 2003. A role for Stat5 in CD8+ T cell homeostasis. J Immunol 170(1):210-217.
63. Kirken RA, et al. 1997. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem 272(22):14098-14103.
64. Kisseleva T, et al. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285(1-2): 1-24.
65. Lecine P, et al. 1996. Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol Cell Biol 16(12):6829-6840.
66. Leonard WJ. 2001. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73(3):271-277.
67. Leung S, Li X, Stark GR. 1996. STATs find that hanging together can be stimulating. Science 273(5276):750-751.
68. Levine RL, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387-397.
69. Levy DE, Darnell JE, Jr. 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651-662.
70. Liao W, et al. 2008. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat Immunol 9(11):1288-1296.
71. Liao W, et al. 2011. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 12(6):551-559.
72. Lin JX, et al. 2012. Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36(4):586-599.
73. Lin JX, Leonard WJ. 2000. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19(21):2566-2576.
74. Lin TS, Mahajan S, Frank DA. 2000. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19(21): 2496-2504.
75. Litterst CM, et al. 2003. NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alphahelical region of the STAT5 transactivation domain. J Biol Chem 278(46):45340-45351.
76. Liu X, et al. 1995. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 92(19):8831-8835.
77. Liu X, et al. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11(2):179-186.
78. Liu X, Robinson GW, Hennighausen L. 1996. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 10(12):1496-1506.
79. Look DC, et al. 1995. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 270(51):30264-30267.
80. Marg A, et al. 2004. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 165(6):823-833.
81. Meinke A, et al. 1996. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 16(12):6937-6944.
82. Meyer T, et al. 2004. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J Biol Chem 279(18):18998-19007.
83. Meyer WK, et al. 1997. Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription. J Biol Chem 272(50):31821-31828.
84. Mikita T, et al. 1996. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 16(10):5811-5820.
85. Mitchell TJ, Whittaker SJ, John S. 2003. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res 63(24):9048-9054.
86. Miyoshi K, et al. 2001. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155(4): 531-542.
87. Mizuki M, et al. 2003. Oncogenic receptor tyrosine kinase in leukemia. Cell Mol Biol (Noisy-le-grand) 49(6):907-922.
88. Moriggl R, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10(2): 249-259.
89. Moriggl R, et al. 2005. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell 7(1):87-99.
90. Muhlethaler-Mottet A, et al. 1998. Activation of theMHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8(2):157-166.
91. Mui AL, et al. 1995. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol 57(5):799-803.
92. Murphy TL, et al. 2000. Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation. Mol Cell Biol 20(19):7121-7131.
93. Mziaut H, et al. 2006. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 8(5):435-445.
94. Nakajima H, et al. 1997. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 7(5): 691-701.
95. Nakayama J, et al. 2009. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 113(7):1483-1492.
96. Nanashima N, et al. 2005. Nuclear localization of STAT5A modified with O-linked N-acetylglucosamine and early involution in the mammary gland of Hirosaki hairless rat. J Biol Chem 280(52):43010-43016.
97. Nevalainen MT, et al. 2004. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22(11):2053-2060.
98. O'Shea JJ, et al. 2000. Jaks and stats as therapeutic targets. Ann Rheum Dis 59 Suppl 1:i115-i118.
99. O'Shea JJ, Gadina M, Schreiber RD. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl:S121-S131.
100. Onishi M, et al. 1998. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 18(7):3871-3879.
101. Park JH, et al. 2007. 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the selfspecificity of the TCR. Nat Immunol 8(10):1049-1059.
102. Park SH, Waxman DJ. 2001. Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3beta: impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression. J Biol Chem 276(46):43031-43039.
103. Peck AR, et al. 2011. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 29(18):2448-2458.
104. Pesu M, et al. 2000. Interleukin-4-induced transcriptional activation by stat6 involvesmultiple serine/threonine kinase pathways and serine phosphorylation of stat6. Blood 95(2):494-502.
105. Pfitzner E, et al. 1998. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 12(10):1582-1593.
106. Rane SG, Reddy EP. 2002. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21(21):3334-3358.
107. Rathinam C, et al. 2008. The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells. Genes Dev 22(8):992-997.
108. Ren S, et al. 2002. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21(27):4335-4339.
109. Rycyzyn MA, Clevenger CV. 2002. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99(10):6790-6795.
110. Sato N, et al. 2005. Nuclear retention of STAT3 through the coiled-coil domain regulates its activity. Biochem Biophys Res Commun 336(2):617-624.
111. Schaefer TS, Sanders LK, Nathans D. 1995. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci USA 92(20):9097-9101.
112. Schaller-Schonitz M, et al. 2014. BCR-ABL affects STAT5A and STAT5B differentially. PLoS One 9(5):e97243.
113. Schindler C, et al. 1992. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257(5071):809-813.
114. Schindler C, Strehlow I. 2000. Cytokines and STAT signaling. Adv Pharmacol 47:113-174.
115. Schindler CW. 2002. Series introduction. JAK-STAT signaling in human disease. J Clin Invest 109(9):1133-1137.
116. Seidel HM, et al. 1995. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 92(7):3041-3045.
117. Sexl V, et al. 2000. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of stat5. Blood 96(6):2277-2283.
118. Shuai K. 2000. Modulation of STAT signaling by STATinteracting proteins. Oncogene 19(21):2638-2644.
119. Shuai K, et al. 1992. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258(5089):1808-1812.
120. Shuai K, et al. 1996. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13(2):247-254.
121. Silva CM, Shupnik MA. 2007. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol 21(7):1499-1512.
122. Snow JW, et al. 2002. STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 99(1):95-101.
123. Snyder M, He W, Zhang JJ. 2005. The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation. Proc Natl Acad Sci USA 102(41):14539-14544.
124. Soldaini E, et al. 2000. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 20(1):389-401.
125. Stocklin E, et al. 1996. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383(6602):726-728.
126. Sultan AS, et al. 2005. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24(5):746-760.
127. Takeda K, Akira S. 2000. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11(3):199-207.
128. Taketani T, et al. 2004. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103(3):1085-1088.
129. Tan SH, Nevalainen MT. 2008. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 15(2):367-390.
130. Tang JZ, et al. 2010. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 151(1):43-55.
131. Teglund S, et al. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93(5):841-850.
132. Tourkine N, et al. 1995. Activation of STAT factors by prolactin, interferon-gamma, growth hormones, and a tyrosine phosphatase inhibitor in rabbit primary mammary epithelial cells. J Biol Chem 270(36):20952-20961.
133. Tran TH, et al. 2010. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 70(4):1711-1721.
134. Tworoger SS, Sluss P, Hankinson SE. 2006. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476-2482.
135. Udy GB, et al. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94(14):7239-7244.
136. Vafaizadeh V, et al. 2010. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 28(5):928-938.
137. Van Etten RA. 2007a. Aberrant cytokine signaling in leukemia. Oncogene 26(47):6738-6749.
138. Van Etten RA. 2007b. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 204(3):461-465.
139. Van Nguyen T, et al. 2012. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell 45(2):210-221.
140. Verdier F, et al. 1998. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol Cell Biol 18(10):5852-5860.
141. Vinkemeier U, et al. 1996. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15(20):5616-5626.
142. Vinkemeier U, et al. 1998. Structure of the amino-terminal protein interaction domain of STAT-4. Science 279(5353):1048-1052.
143. Wagner KU, Rui H. 2008. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 13(1):93-103.
144. Wakao H, Gouilleux F, Groner B. 1994. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13(9):2182-2191.
145. Walker SR, Xiang M, Frank DA. 2014. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 382(1):616-621.
146. Wang RA, et al. 2003. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol 161(3):583-592.
147. Weber-Nordt RM, et al. 1996. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88(3):809-816.
148. Wernig G, et al. 2006. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107(11):4274-4281.
149. Xia Z, et al. 2001. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 25(6):473-482.
150. Xu BC, et al. 1996. Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor. J Biol Chem 271(33):19768-19773.
151. Xu D, Qu CK. 2008. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 13:4925-4932.
152. Yamashita H, et al. 1998. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273(46):30218-30224.
153. Yamashita H, et al. 2001. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 183(1-2):151-163.
154. Yamashita H, et al. 2003. Naturally occurring dominantnegative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22(11):1638-1652.
155. Yamashita H, et al. 2006. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13(3): 885-893.
156. Yao Z, et al. 2006. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 103(4):1000-1005.
157. Ye D, et al. 2006. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107(12): 4917-4925.
158. Yokoyama N, ReichNC, MillerWT. 2001. Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res 21(6):369-378.
159. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798-809.
160. Zhang JJ, et al. 1996. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci USA 93(26):15092-15096.
161. Zhang X, Darnell JE, Jr. 2001. Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J Biol Chem 276(36):33576-33581.
162. Zhu J, et al. 2003. Stat5 activation plays a critical role in Th2 differentiation. Immunity 19(5):739-748.
163. Zhu J, Paul WE. 2010. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 238(1):247-262.
164. Zhu M, et al. 1999. Functional association of Nmi with Stat5 and Stat1 in IL-2-and IFNgamma-mediated signaling. Cell 96(1):121-130.